Form 13-F position report

PTC THERAPEUTICS INC

Reported by The Goldman Sachs Group Inc

PTCT CUSIP 69366J200 Manager CIK 0000886982

Reported 775,753 shares, up 173,088 (28.7%) from the prior quarter.

Reported value 23.4%; share count 28.7% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 775,753 Quarter-end amount reported
Reported value $37,887,776 Fair value at quarter end
Consecutive quarters held 44 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 21004000
2022-03-31 8522000
2022-06-30 19877000
2022-09-30 25375000
2022-12-31 20345908
2023-03-31 21927916
2023-06-30 17334855
2023-09-30 7616845
2023-12-31 14510174
2024-03-31 13963811
2024-06-30 24193795
2024-09-30 30512561
2024-12-31 34515172
2025-03-31 30711808
2025-06-30 37887776
2025-09-30 53785221
2025-12-31 77713992
2026-03-31 56386500
2026-06-30 50430408
2026-09-30 105230899

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for PTC THERAPEUTICS INC held by The Goldman Sachs Group Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 1,624,435 +1,006,188 (162.7%) < 0.01% $105,230,899 2026-11-16
Q2 2026 Reduced 618,247 -209,384 (-25.3%) < 0.01% $50,430,408 2026-08-14
Q1 2026 Reduced 827,631 -195,460 (-19.1%) < 0.01% $56,386,500 2026-05-15
Q4 2025 Added 1,023,091 +146,682 (16.7%) < 0.01% $77,713,992 2026-02-10
Q3 2025 Added 876,409 +100,656 (13.0%) < 0.01% $53,785,221 2025-11-14
Q2 2025 Added 775,753 +173,088 (28.7%) < 0.01% $37,887,776 2025-08-14
Q1 2025 Reduced 602,665 -161,960 (-21.2%) < 0.01% $30,711,808 2025-05-09
Q4 2024 Reduced 764,625 -57,816 (-7.0%) < 0.01% $34,515,172 2025-02-11
Q3 2024 Added 822,441 +31,277 (4.0%) < 0.01% $30,512,561 2024-11-14
Q2 2024 Added 791,164 +311,143 (64.8%) < 0.01% $24,193,795 2024-08-13
Q1 2024 Reduced 480,021 -46,473 (-8.8%) < 0.01% $13,963,811 2024-05-15
Q4 2023 Added 526,494 +186,608 (54.9%) < 0.01% $14,510,174 2024-02-13
Q3 2023 Reduced 339,886 -86,346 (-20.3%) < 0.01% $7,616,845 2023-11-14
Q2 2023 Reduced 426,232 -26,450 (-5.8%) < 0.01% $17,334,855 2023-08-15
Q1 2023 Reduced 452,682 -80,352 (-15.1%) < 0.01% $21,927,916 2023-05-11
Q4 2022 Added 533,034 +27,556 (5.5%) < 0.01% $20,345,908 2023-02-13
Q3 2022 Added 505,478 +9,298 (1.9%) < 0.01% $25,375,000 2022-11-14
Q2 2022 Added 496,180 +267,773 (117.2%) < 0.01% $19,877,000 2022-08-15
Q1 2022 Reduced 228,407 -298,926 (-56.7%) < 0.01% $8,522,000 2022-05-16
Q4 2021 Added 527,333 +299,114 (131.1%) < 0.01% $21,004,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

321 managers reported PTC THERAPEUTICS INC for Q2 2025.

Managers reporting PTC THERAPEUTICS INC in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 8,847,467 +240,095 < 0.01% $432,110,288 48 qtrs
RTW INVESTMENTS LP Added 7,746,415 +263,288 5.39% $378,334,909 35 qtrs
BlackRock Inc Reduced 7,480,432 -287,785 < 0.01% $365,344,299 4 qtrs
ARMISTICE CAPITAL LLC Reduced 4,735,464 -699,379 3.99% $231,280,062 27 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 4,694,138 -725,034 0.04% $229,261,699 48 qtrs
JANUS HENDERSON GROUP PLC Added 3,175,015 +258,286 0.08% $155,010,652 26 qtrs
STATE STREET CORPORATION Added 2,996,454 +541,558 < 0.01% $146,346,813 48 qtrs
TORONTO DOMINION BANK Reduced 2,445,958 -167,238 0.2% $119,460,589 3 qtrs
D E Shaw & Co Inc Added 2,437,697 +992,418 0.08% $119,057,122 40 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,934,593 +60,707 < 0.01% $94,497,190 48 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
CMN

Voting authority reported

Sole
771,747
Shared
0
None
4,006

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.